Watson Confirms Vyvanse Patent Challenge

Watson Pharmaceuticals, Inc. WPI today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market lisdexamfetamine dimesylate capsules. Watson's lisdexamfetamine dimesylate capsules are a generic version of Shire LLC's Vyvanse®. Vyvanse® is a prescription medicine for the treatment of Attention Deficit Hyperactivity Disorder in children ages 6 to 17 and adults.